Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies

Oncologist

Volumn 18, Issue 7, 2013, Pages 833-842

  Dewdney, Alice ^a   Cunningham, David ^a   Chau, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemoradiation; Magnetic resonance imaging; Neoadjuvant treatment; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UFT;

ADJUVANT THERAPY; ANASTOMOSIS LEAKAGE; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG RESPONSE; FOLLOW UP; GENE MUTATION; HISTOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; MALE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84880680568     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0022     Document Type: Article

References (69)

1. Heald RJ, Moran BJ, Ryall RD et al. Rectal cancer: The Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-899.
2. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26:303-312.
3. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observational study. BMJ 2006;333:779.
4. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123.
5. Folkesson J, Birgisson H, Pahlman L et al. Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23:5644-5650.
6. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006;24:4620-4625.
7. Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30: 1926-1933.
8. van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575-582.
9. Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001;16:298-304.
10. Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer:Apooled analysis. J Clin Oncol 2004;22:1785-1796.
11. Gunderson LL, Jessup JM, Sargent DJ et al. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 2010;28:256-263.
12. Dresen RC, Peters EE, Rutten HJ et al. Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J Surg Oncol 2009;35: 1071-1077.
13. Ouchi K, Sugawara T, Ono H et al. Histologic features and clinical significance of venous invasion in colorectal carcinoma with hepatic metastasis. Cancer 1996;78:2313-2317.
14. Smith NJ, Barbachano Y, Norman AR et al. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008;95:229-236.
15. den DM, Putter H, Collette L et al. The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer 2009;45: 1175-1183.
16. Puli SR, Bechtold ML, Reddy JB et al. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. Dig Dis Sci 2010;55:1221-1229.
17. Puli SR, Reddy JB, Bechtold ML et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: A meta-analysis and systematic review. Ann Surg Oncol 2009;16:1255-1265.
18. Puli SR, Bechtold ML, Reddy JB et al. Howgood is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009;16:254-265.
19. Extramural depth of tumor invasion at thinsection MR in patients with rectal cancer: Results of the MERCURY Study. Radiology 2007;243:132-139.
20. Taylor FG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: A prospective, multicenter, European study. Ann Surg 2011; 253:711-719.
21. Taylor FG, Quirke P, Heald RJ et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011;98:872-879.
22. Shihab OC, Taylor F, Bees N et al. Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. Br J Surg 2011;98:1798-1804.
23. Pedersen BG, Moran B, Brown G et al. Reproducibility of depth of extramural tumor spread and distance to circumferential resection margin at rectal MRI: Enhancement of clinical guidelines for neoadjuvant therapy. AJR Am J Roentgenol 2011;197: 1360-1366.
24. Al-Sukhni E, Milot L, Fruitman M et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: A systematic review and meta-analysis. Ann Surg Oncol 2012;19:2212-2223.
25. Kikuchi R, Takano M, Takagi K et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995;38:1286-1295.
26. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:1014-1020.
27. Peng J, Chen W, Venook AP et al. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer 2011;10:37-41.
28. Wu ZY, Zhao G, Chen Z et al. Oncological outcomes of transanal local excision for high risk T(1) rectal cancers. World J Gastrointest Oncol 2012;4: 84-88.
29. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93: 1215-1223.
30. Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus longcourse chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol 2012;30:3827-3833.
31. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 2009;373: 811-820.
32. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
33. Braendengen M, Tveit KM, Bruheim K et al. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized Phase III study. Int J Radiat Oncol Biol Phys 2011;81: 1017-1024.
34. Marijnen CA, Van de Velde CJ, Putter H et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2005;23:1847-1858.
35. Peeters KC, Van de Velde CJ, Leer JW et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased boweldys function in irradiated patients-A Dutch colorectal cancer group study. J Clin Oncol 2005;23:6199-6206.
36. Stephens RJ, Thompson LC, Quirke P et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: Data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010;28: 4233-4239.
37. Birgisson H, Pahlman L, Gunnarsson U et al. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005;23:6126-6131.
38. Hofheinz RD, Wenz F, Post S et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-588.
39. Roh MS, Yothers GA, O'Connell MJ et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011;29:3503.
40. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009;373: 821-828.
41. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: Report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:15-24.
42. Pach R, Kulig J, Richter P et al. Randomizedclinical trial on preoperative radiotherapy 25 Gy in rectal cancer-treatment results at 5-year follow-up. Langenbecks Arch Surg 2012;397:801-807.
43. Chua YJ, Barbachano Y, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase 2 trial. Lancet Oncol 2010;11:241-248.
44. Dewdney A, Cunningham D, Tabernero J et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30:1620-1627.
45. Schrag D, Weiser MR, Goodman KA et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol 2010;28:3511.
46. Fernandez-Martos C, Estevan R, Salud A et al. Neoadjuvant capecitabine, oxliplatin, and bevacizumab(CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. J Clin Oncol 2012;30:3586.
47. Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: Influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002;52:1092-1098.
48. Aschele C, Cionini L, Lonardi S et al. Primary tumorresponse to preoperative chemoradiation with or without oxaliplatin in locallyadvancedrectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773-2780.
49. Gerard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-1644.
50. Gerard JP, Azria D, Gourgou-Bourgade S et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012;30:4558-4565.
51. Rodel C, Liersch T, Becker H et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679-687.
52. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:824-830.
53. Nogue M, Salud A, Vicente P et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locallyadvancedrectal cancer:The AVACROSS study. The Oncologist 2011;16:614-620.
54. Willett CG, Boucher Y, Duda DG et al. Surrogate markers for antiangiogenic therapy and doselimiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139.
55. Willett CG, Duda DG, di TE et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 2009;27:3020-3026.
56. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011;22:1535-1546.
57. Van Cutsem E, Kohne CH, Lang I et al. Cetuximabplus irinotecan, fluorouracil, andleucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
58. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer-Is the water getting muddy? Acta Oncol 2010;49: 278-286.
59. Cummings BJ. Is there a limit to dose escalation for rectal cancer? Clin Oncol (R Coll Radiol) 2007;19:730-737.
60. Ortholan C, Romestaing P, Chapet O et al. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int J Radiat Oncol Biol Phys 2012;83:e165-e171.
61. Jakobsen AKM, Appelt AL, Lindebjerg J et al. The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: Preliminary results of a phase III trial. J Clin Oncol 2011;29:3512.
62. Samuelian JM, Callister MD, Ashman JB et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2012;82:1981-1987.
63. Garofalo M, Moughan J, Hong T et al. RTOG 0822: A phase II study of preoperative (PREOP) chemoradiotherapy (CRT) utilizing IMRT in combination with capecitabine (C) and oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Rad Oncol Biol Phys 2011;81:S3-S4.
64. Schou JV, Larsen FO, Rasch L et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 2012;23:2627-2633.
65. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74: 673-688.
66. Grade M, Wolff HA, Gaedcke J et al. Themolecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg 2012;397:543-555.
67. He Y, Van't Veer LJ, Mikolajewska-Hanclich I et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009;15: 6956-6962.
68. He Y, Van't Veer LJ, Lopez-Yurda M et al. Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences? Clin Cancer Res 2010;16:6179.
69. Patel UB, Taylor F, Blomqvist L et al. Magnetic resonanceimaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29:3753-3760.